AbbVie Inc. (ABBV) FY2024 YTD Q3 P&L / Income Statement

AbbVie Inc. (ABBV) FY2024 YTD Q3 P&L / Income Statement

Income statement for 2024-01-01 through 2024-09-30. View: Key Product Portfolio by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenues

41,232,000,000 US dollars

Cost of products sold

12,508,000,000 US dollars

Gross profit (calculated)

28,724,000,000 US dollars

Operating expenses (calculated)

18,097,000,000 US dollars

Operating earnings

10,627,000,000 US dollars

Other income (expense), net (calculated)

negative 4,642,000,000 US dollars

Earnings before income tax expense

5,985,000,000 US dollars

Income tax expense

1,676,000,000 US dollars

Net earnings

4,309,000,000 US dollars

Aesthetics - Botox Cosmetic

2,033,000,000 US dollars

Aesthetics - Juvederm Collection

898,000,000 US dollars

Aesthetics - Other Aesthetics

947,000,000 US dollars

Eye Care - Alphagan/Combigan

170,000,000 US dollars

Eye Care - Lumigan/Ganfort

310,000,000 US dollars

Eye Care - Other Eye Care

632,000,000 US dollars

Eye Care - Ozurdex

374,000,000 US dollars

Eye Care - Restasis

110,000,000 US dollars

Hematologic Oncology - Epkinly

106,000,000 US dollars

Hematologic Oncology - Imbruvica

2,499,000,000 US dollars

Hematologic Oncology - Venclexta

1,928,000,000 US dollars

Immunology - Humira

7,311,000,000 US dollars

Immunology - Rinvoq

4,137,000,000 US dollars

Immunology - Skyrizi

7,940,000,000 US dollars

Neuroscience - Botox Therapeutic

2,410,000,000 US dollars

Neuroscience - Duodopa

339,000,000 US dollars

Neuroscience - Other Neuroscience

238,000,000 US dollars

Neuroscience - Qulipta

457,000,000 US dollars

Neuroscience - Ubrelvy

703,000,000 US dollars

Neuroscience - Vraylar

2,343,000,000 US dollars

Other Key Products - Linzess/Constella

721,000,000 US dollars

Other Key Products - Mavyret

1,020,000,000 US dollars

Undisclosed (calculated)

3,606,000,000 US dollars

Acquired IPR&D and milestones

1,183,000,000 US dollars

Research and development

6,017,000,000 US dollars

Selling, general and administrative

10,897,000,000 US dollars

Other operating income

0 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to AbbVie Inc.: $4.30 B; to noncontrolling interests: $9.00 M.